Desarrollo y validación de la escala de planificación centrada en la persona (E-PCP)

  1. Cuervo Rodríguez, Tania 1
  2. Iglesias García, M.ª Teresa 1
  1. 1 Universidad de Oviedo
    info

    Universidad de Oviedo

    Oviedo, España

    ROR https://ror.org/006gksa02

Zeitschrift:
Siglo Cero: Revista Española sobre Discapacidad Intelectual

ISSN: 2530-0350

Datum der Publikation: 2021

Ausgabe: 52

Nummer: 3

Seiten: 119-139

Art: Artikel

DOI: 10.14201/SCERO2021523119139 DIALNET GOOGLE SCHOLAR lock_openOpen Access editor

Andere Publikationen in: Siglo Cero: Revista Española sobre Discapacidad Intelectual

Zusammenfassung

Much research has been developed concerning the application and effects of Person-Centered Planning (PCP). Nevertheless, there are no standardized instruments adapted to the Spanish context. This study seeks to design and validate the Person Centered Planning Scale (E-PCP) in order to offer a valid and reliable instrument to do so. For its construction and content validation, the bibliographic review has been used and the Delphi technique has been applied. The resulting scale has been applied to a sample of 102 professionals who work in intellectual disability care centers in Asturias, which has allowed the analysis of their psychometric properties. In order to analyze the construct validity, a cross-validation was carried out, using exploratory factor analysis (AFE) and confirmatory factor analysis (CFA). Results show a scale with a good reliability (? = ,96), explaining the 58 % of variance and with a Single-factor structure made up by 16 items. Its short length, reliability and validity indicate that this instrument can be useful for both research and professional practice.

Bibliographische Referenzen

  • Arnold WN. Vincent van Gogh: chemicals, crises and creativity. Basilea: Birkhäuser; 1992. p. 168-9.
  • Arnold WN, Loftus Ls. Xanthopsia and van Gogh´s Yellow Palette. Eye. 1991: ;5 ( Pt 5):503-10.
  • Ayme A., Butor M, Sicard M. Triple suite en jaune à la gloire de Van Gogh. Paris: Traversière; 1987. p. 14.
  • Blumer D. The illness of Vincent van Gogh. Am J Psychiatry. 2002; 159(4):519-26.
  • Bonkovsky HL, Cable EE, Cable JW, Donohue SE, White EC, Greene YJ, et al. Porphyrogenic properties of the terpenes camphor, pinene, and thujone (with a note on historic implications for absinthe and the illness of Vincent van Gogh). Biochem Pharmacol. 1992; 9; 43 (11): 2359-68.
  • Douglas K. El hijo del trapero. Barcelona: Ediciones B S.A; 1988. p. 20.
  • Gastaut H. La maladie de Vincent Van Gogh envisagée a la lumière des conceptions nouvelles sur l’épilepsie psychomotrice [Vincent van Gogh’s disease seen in the light of new concepts of psychomotor epilepsy]. Ann Med Psychol (Paris). 1956;114(2):196-238.
  • González Luque FJ, Montejo González AL. Vincent van Gogh y los colores tóxicos de Saturno. Relato autobiográfico de un envenenamiento por plomo. Salamanca; 2004.
  • González Luque FJ, Montejo González AL. Vincent van Gogh: poseído por el color y la luz. Madrid: Laboratorios Juste; 1997.
  • Kaufman I, FLieger L, Bernstein L y cols. Van Gogh Had Meniere´s Disease and Not Epilepsy. JAMA. 1990; 264 (4): 491-3.
  • Kyaga S, Landén M, Boman M, Hultman CM, Långströmad N, Lichtensteina P. Mental illness, suicide and creativity: 40-year prospective total population study. J Psychiatr Res. 2013; 47 (1): 83-90.
  • Loftus LS, Arnold WN. Vincent van Gogh´s illness: acute intermittent porphyria? BMJ 1991; 303 (6817): 1589-91.
  • Murphy E. Historia de los grandes burdeles del mundo. Madrid: Ediciones Temas de Hoy, Madrid 1989. p 327-8
  • Núñez G. ¿Dónde está el «doctor Gachet»? La Razón. 3 de julio de 2016.
  • Pagoaga A, Interiano V, Chirinos A, Meza X. Manifestaciones neuropsiquiátricas de la porfiria. Revista Hondureña del Posgrado de Psiquiatría. 2014 (Edición especial) 32-6.
  • Palacios L, Botero JS, Vélez C. Vincent Van Gogh y sus posibles afecciones neuropsiquiátricas. Repert Med Cir. 2018; 27(2): 131-41.
  • Perruchot H. La vie de Van Gogh. París: Hachette; 1954.
  • Price AL, Marzani-Nissen G. Bipolar disorders: a review. Am Fam Physician. 2012; 85(5): 483-93.
  • Richardson BA, Rusinyak A, Rodning CB. Neuroanatomical Interpretation of the Painting Starry Night by Vincent van Gogh. Neurosurgery. 2017; 81 (3): 389-96.
  • Roque G. Van Gogh, teórico del color. Anales del Instituto de Investigaciones Esteticas 1997; 19(70): 77-96.
  • Russo EB. Taming THC: Potentital cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Phamacol. 2011; 163(7): 1344-64.
  • Siegal N. What Ailed van Gogh? Doctors Weigh In. The New York Times, september 15, 2016.
  • Strik WK. La enfermedad psíquica de van Gogh. Alcmeón 19, Revista Argentina de Clínica Neuropsiquiátrica. 1996 (4).
  • Torrens Mèlich M. Patología dual: situación actual y retos de futuro. Adicciones. 2008; 20(4): 315-19.
  • Tralbault ME. Vincent van Gogh, le mal aimé. Londres: Macmillan. 1981. p. 16.
  • Trotter RJ. Geschwind´s Syndrome: Van Gogh´s Malady. Psychology Today. 1985; 19(11), p. 46.
  • Vallejo-Nágera JA. Locos egregios. El crepúsculo de van Gogh. Barcelona: Editorial Planeta 1988.
  • Van Gogh V. Cartas a Thèo. Barcelona: Idea Books; 2003.
  • Vasuyattakul S, Lertpattanasuwan N, Vareesangthip K, Nimmannit S, Nilwarangkur S. A negative anion gap as a clue to diagnose bromide intoxication. Nephron. 1995; 69(3):311-3.
  • Yasuda K. Was Van Gogh suffering from Mèniére´s disease?. Jibi to rinsho. 1979; 25 (6): 1427-39.
Fuente de los datos: Dialnet